Venetoclax Alternatives Compared
Venetoclax | Imbruvica (ibrutinib) | Jaypirca (pirtobrutinib) |
|
---|
Venetoclax | Imbruvica (ibrutinib) | Jaypirca (pirtobrutinib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia. Venetoclax may also be used for purposes not listed in this medication guide. |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Prescribed for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia. Jaypirca may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||||||||||
More about Venetoclax | More about Imbruvica (ibrutinib) | More about Jaypirca (pirtobrutinib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Venetoclax has an average rating of 9.0 out of 10 from a total of 23 ratings on Drugs.com. 91% of reviewers reported a positive effect, while 0% reported a negative effect. |
Imbruvica has an average rating of 6.6 out of 10 from a total of 69 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Jaypirca has an average rating of 8.8 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Venetoclax side effects |
View all Imbruvica side effects |
View all Jaypirca side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Imbruvica prices |
View all Jaypirca prices |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Venclexta |
N/A |
N/A |
||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
26 hours |
6 hours |
19 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 462 drugs are known to interact with Venetoclax:
|
A total of 507 drugs are known to interact with Imbruvica:
|
A total of 734 drugs are known to interact with Jaypirca:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
November 13, 2013 |
January 27, 2023 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.